2026 – Stryker Continues Expansion of XprESS® ENT Dilation System AdoptionStryker continued strengthening its ENT device portfolio through its XprESS® ENT dilation system, a balloon dilation technology used for chronic rhinosinusitis and Eustachian tube dysfunction procedures. The system incorporates features such as navigated confirmation compatibility, integrated light-guided placement, and multiple balloon sizes designed for different sinus anatomies and patient populations.
2026 – Increased Adoption of Navigation-Assisted Balloon Sinus Dilation ProceduresENT device manufacturers continued advancing navigation-enabled sinus dilation technologies that combine balloon catheter systems with image-guided surgical workflows. These solutions aim to improve procedural accuracy, physician confidence, and access to complex sinus anatomy during minimally invasive procedures.
2025–2026 – MedTech Companies Focus on Minimally Invasive Sinus Treatment TechnologiesLeading ENT device companies continued investing in minimally invasive solutions for chronic rhinosinusitis, including balloon sinus dilation systems, sinus access devices, and hybrid functional endoscopic sinus surgery (FESS) technologies. The shift toward outpatient and office-based procedures remains a key factor influencing product development.
2025 – Stryker Expands ENT Procedural Solutions Portfolio with Balloon Dilation and Navigation TechnologiesStryker continued promoting its ENT technology ecosystem, including the XprESS® balloon dilation platform and ENT navigation solutions designed to support precise sinus access and dilation procedures. The company highlights applications across frontal, maxillary, sphenoid sinus pathways, and Eustachian tube dilation.